Atypical Antipsychotic-induced Weight Gain: Insights into Mechanisms of Action

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2011 Dec 3

PMID 22133326

Citations 54

Authors

James L Roerig

Kristine J Steffen

James E Mitchell

Affiliations

Soon will be listed here.

Abstract

Prescriptions for second-generation antipsychotics (SGAs) have surpassed those for first-generation agents in the treatment of schizophrenia and bipolar disorder. While SGAs have the benefit of a much reduced risk of causing movement disorders, they have been associated with weight gain and metabolic effects. These adverse reactions are not uncommon, and threaten to have a significant impact on the patient's health over the long-term treatment that the patient requires. Currently, the aetiology of these effects is not known. This article reviews the data exploring the weight gain phenomenon. The literature was reviewed from searches of PubMed and the references of major articles in the field. The SGAs present a heterogeneous risk for weight gain. In addition, different individuals receiving the same drug can exhibit substantially different weight changes. This pattern suggests that a group of factors are associated with the weight gain phenomenon rather than a single mechanism. Coupled with the genetic profile that the patient brings to the treatment, the risk for SGA-induced weight gain will be different for different drugs and different individuals. Targets for exploration of the weight gain phenomenon include receptor interactions involving serotonin, histamine, dopamine, adrenergic, cannabinoid and muscarinic receptors. The association of SGA-induced weight gain and the role of orexigenic and anorexigenic peptides are reviewed. Also, a brief discussion of genetic factors associated with SGA-induced weight gain is presented, including that of the serotonin 5-HT(2C) receptor gene (HTR2C) and the cannabinoid 1 receptor gene (CNR1). The most promising data associated with SGA-induced weight gain include investigations of the histamine H(1), 5-HT(2A), 5-HT(2C), muscarinic M(3) and adrenergic receptors. In addition, work in the genetic area promises to result in a better understanding of the variation in risk associated with different individuals.

Citing Articles

Exploring the effects of probiotics on olanzapine-induced metabolic syndrome through the gut microbiota.

Mushraf S, Chawla K, Fayaz S, Mathew A, Reddy G, Kappettu Gadahad M Gut Pathog. 2024; 16(1):77.

PMID: 39709451 PMC: 11662719. DOI: 10.1186/s13099-024-00664-2.

Guideline for pharmacological treatment of schizophrenia 2022.

Neuropsychopharmacol Rep. 2024; 45(1):e12497.

PMID: 39587785 PMC: 11666347. DOI: 10.1002/npr2.12497.

Mechanisms Involved in the Link between Depression, Antidepressant Treatment, and Associated Weight Change.

Kukucka T, Ferencova N, Visnovcova Z, Ondrejka I, Hrtanek I, Kovacova V Int J Mol Sci. 2024; 25(8).

PMID: 38674096 PMC: 11050075. DOI: 10.3390/ijms25084511.

Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester, UK.

Heald A, Daly C, Warner-Levy J, Williams R, Meehan C, Livingston M Ann Gen Psychiatry. 2024; 23(1):1.

PMID: 38172807 PMC: 10763024. DOI: 10.1186/s12991-023-00485-8.

Clozapine suppresses NADPH oxidase activation, counteracts cytosolic HO, and triggers early onset mitochondrial dysfunction during adipogenesis of human liposarcoma SW872 cells.

Blandino G, Fiorani M, Canonico B, De Matteis R, Guidarelli A, Montanari M Redox Biol. 2023; 67:102915.

PMID: 37866162 PMC: 10623370. DOI: 10.1016/j.redox.2023.102915.

References

Mailman R, Murthy V . Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr Pharm Des. 2009; 16(5):488-501. PMC: 2958217. DOI: 10.2174/138161210790361461. View

Fukagawa K, Sakata T, Shiraishi T, Yoshimatsu H, Fujimoto K, Ookuma K . Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol. 1989; 256(3 Pt 2):R605-11. DOI: 10.1152/ajpregu.1989.256.3.R605. View

Nasrallah H, Meyer J, Goff D, McEvoy J, Davis S, Stroup T . Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86(1-3):15-22. DOI: 10.1016/j.schres.2006.06.026. View

Reynolds G, Zhang Z, Zhang X . Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003; 160(4):677-9. DOI: 10.1176/appi.ajp.160.4.677. View

Wren A, Seal L, Cohen M, Brynes A, Frost G, Murphy K . Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86(12):5992. DOI: 10.1210/jcem.86.12.8111. View

Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier A . Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002; 87(6):2918-23. DOI: 10.1210/jcem.87.6.8599. View

Black M, Stevens R, Rogacki N, Featherstone R, Senyah Y, Giardino O . AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl). 2010; 215(1):149-63. DOI: 10.1007/s00213-010-2124-0. View

Saddichha S, Ameen S, Akhtar S . Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008; 28(1):27-31. DOI: 10.1097/jcp.0b013e3181602fe6. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

10.

Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y . Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol. 2005; 20(1):75-9. DOI: 10.1177/0269881105056647. View

11.

Savoy Y, Ashton M, Miller M, Nedza F, Spracklin D, Hawthorn M . Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophr Bull. 2008; 36(2):410-8. PMC: 2833119. DOI: 10.1093/schbul/sbn104. View

12.

Reynolds G, Templeman L, Zhang Z . The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(6):1021-8. DOI: 10.1016/j.pnpbp.2005.03.019. View

13.

Parada M, Hernandez L, Paez X, Baptista T, Puig de Parada M, de Quijada M . Mechanism of the body weight increase induced by systemic sulpiride. Pharmacol Biochem Behav. 1989; 33(1):45-50. DOI: 10.1016/0091-3057(89)90427-9. View

14.

Flegal K, Carroll M, Ogden C, Curtin L . Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303(3):235-41. DOI: 10.1001/jama.2009.2014. View

15.

Huang X, Han M, Huang X, Zavitsanou K, Deng C . Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res. 2006; 171(2):355-62. DOI: 10.1016/j.bbr.2006.03.040. View

16.

Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J . Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6):829-36. DOI: 10.4088/JCP.08m04905. View

17.

van der Lende T, Te Pas M, Veerkamp R, Liefers S . Leptin gene polymorphisms and their phenotypic associations. Vitam Horm. 2005; 71:373-404. DOI: 10.1016/S0083-6729(05)71013-X. View

18.

Perez-Iglesias R, Vazquez-Barquero J, Amado J, Berja A, Garcia-Unzueta M, Pelayo-Teran J . Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol. 2008; 28(3):289-95. DOI: 10.1097/JCP.0b013e318172b8e6. View

19.

Murashita M, Kusumi I, Hosoda H, Kangawa K, Koyama T . Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology. 2007; 32(7):777-84. DOI: 10.1016/j.psyneuen.2007.05.007. View

20.

Kinon B, Kaiser C, Ahmed S, Rotelli M, Kollack-Walker S . Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005; 25(3):255-8. DOI: 10.1097/01.jcp.0000161501.65890.22. View